Core Insights - Pulse Biosciences, Inc. has initiated the NANOCLAMP AF Study for treating atrial fibrillation, marking a significant step in its clinical research efforts [1] Company Developments - The first patient has been enrolled in the NANOCLAMP AF Study, with the procedure successfully completed at St. Helena Hospital in California [1] - The procedure utilized the nPulse™ Cardiac Surgical System, which is based on the company's proprietary Nanosecond Pulsed Field Ablation™ technology [1] - The company recently received FDA approval, which supports the advancement of its innovative treatment approach [1]

Core Insights - Pulse Biosciences, Inc. announced late-breaking clinical study results from its nPulse™ Cardiac Surgical System during the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark [1] Company Overview - Pulse Biosciences is leveraging its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology [1] Clinical Study Details - The feasibility study aims to assess the initial safety and effectiveness of the nPulse™ technology in a first-in-human context [1]